Pierre Fabre Acquires Worldwide Rights for PFL-721 and PFL-241

Laboratoires Pierre Fabre has announced the acquisition of worldwide rights from Antares Therapeutics, formerly Scorpion Therapeutics, for two EGFR mutant-selective inhibitors, PFL-721 and PFL-241. These compounds, previously known as STX-721 and STX-241, are promising in the development of therapeutic options for unmet medical needs in non-small cell lung cancer (NSCLC). PFL-721 is specifically a mutant-selective inhibitor targeting exon 20 of EGFR and HER2, set to enter dose optimization in initial human trials. PFL-241, a fourth-generation brain-penetrating EGFR selective inhibitor, is advancing in dose escalation trials to target C797S resistance mutations in NSCLC patients. With this deal, Pierre Fabre will now manage the clinical development of these drugs. The agreement further consolidates Pierre Fabre's R&D portfolio, which includes molecules like exarafenib and PFL-002. The company emphasizes its commitment to advancing precision treatments for underserved patient populations. EGFR mutations are implicated in 14 to 38% of NSCLC cases, varying by region.